FDA questions Amgen drug for prostate cancer

Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.

Study Compares 3 Common Prostate Cancer Treatments

TUESDAY, Jan. 31 (HealthDay News) -- Experts comparing three leading prostate cancer therapies find external beam radiation therapy to be more toxic and expensive than either surgery or a more localized form of radiation therapy known as brachytherapy.